國(guó)際新聞精選周二（2017年1月10日）

2017年1月10日 | Filed under: | Posted by: 編輯 D

New drug approvals took a nosedive in 2016. Here are the 22 that made the grade

As the saying goes, what goes up must come down, and to the biopharma industry's chagrin, that’s exactly what happened to new drug approvals in 2016. Last year, the FDA logged 22 new drug OKs, a paltry total compared with the 45 that won a green light in 2015 and 41 in 2014.【閱讀全文】

Silence Therapeutics acquires stake in US rival

Arrowhead Pharmaceuticals is working in the same space as its UK contemporary – gene silencing – and is aiming to provide a new way of tackling difficult-to-treat diseases such as cancer.【閱讀全文】

Japan's Takeda to buy U.S. cancer drug maker Ariad in $5.2 billion deal

Japan's Takeda Pharmaceutical Co. Ltd. said it would buy cancer drug maker Ariad Pharmaceuticals Inc. in a deal valued at $5.20 billion, to beef up its oncology pipeline. Takeda -- which in September revealed it was scouting for multi-billion dollar acquisitions to reduce its dependence on domestic sales -- agreed to pay $24 for each Ariad share, a premium of about 75 percent to its Friday close. 【閱讀全文】

Merrimack falls for $1bn oncology offer from Ipsen

If not a match made in heaven, Ipsen’s $575m up-front deal to acquire Merrimack Pharmaceuticals’ oncology business is a marriage of convenience on both sides. In return for a much-needed cash injection the struggling groom, Merrimack, gives its French bride an easier way into the US oncology market – complete with sales force, manufacturing facilities, and the slightly dull family silver in the form of pancreatic cancer drug Onivyde.【閱讀全文】

Celgene antes up $55M, grabs option to buy the autoimmune upstart Anokion

Celgene’s globetrotting business development team has focused on autoimmune diseases for its latest collaboration/option-to-buy biotech deal. The focus this time: Anokion, a spinout of the Ecole Polytechnique Fédérale de Lausanne. The biotech has been working on antigen-specific immune tolerance tech to retrain the immune system to ignore the rogue signals that spark an autoimmune response against healthy tissue while also restructuring protein therapies to make them invisible to the immune system, possibly opening a path to using some therapies that have been discarded in the past after they triggered an immune response.【閱讀全文】

Allergan bags two new deals, takes option to buy Lysosomal Therapeutics and pays $50M for microbiome pact

Allergan swooped into JP Morgan bearing news of a pair of deals, inking an exclusive option to buy out Lysosomal Therapeutics for its neurodegeneration pipeline and paying $50 million upfront to partner with Assembly Bio on the microbiome. Allergan bought the option on Lysosomal Therapeutics — run by Kees Been — pegging an unspecified price for the biotech after the Phase Ib comes through with data on Parkinson’s disease for their drug LTI-291. Allergan, which is not in the least bit reluctant to pay a premium for what it wants, also added some financial support for R&D at the company, but declined to spell out the details.【閱讀全文】

'Staggering' Price Hikes Resulted In $5 Billion Payday For Ariad Pharma Investors

In October, Bernie Sanders tried to make Ariad Pharmaceuticals, a biotechnology company in Cambridge, Mass., the latest pharmaceutical villain, tweeting that Ariad was an example of the drug industry's "unbelievable" greed. A week later, he followed up with a letter, co-signed by Maryland Representative Elijah Cummings, asking Ariad to explain its "repeated and staggering price increases.”【閱讀全文】

美中藥源原創(chuàng)文章，轉(zhuǎn)載注明出處并添加超鏈接，商業(yè)用途需經(jīng)書(shū)面授權(quán)。
★更多深度解析訪(fǎng)問(wèn)《美中藥源》~

★ 請(qǐng)關(guān)注《美中藥源》微信公眾號(hào) ★